ViThera Pharmaceuticals

ViThera Pharmaceuticals is an early-stage biotechnology company. ViThera's scientists harness the synthetic potential of bacteria to produce therapeutic molecules in vivo, thereby developing a revolutionary new treatment for inflammatory bowel disease (IBD). Our research combines the natural benefits of probiotics with the power of synthetic biology to create game-changing therapies for chronic diseases. Our lead program, VT301, utilizes EnLact technology to treat IBD and is currently in preclinical development.